Realty Income (O) Offers 5.5% Monthly Dividend Yield, Strong REIT Performance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Fool
- Stable Dividend Income: Realty Income boasts a 5.5% dividend yield and has paid dividends for 667 consecutive months, demonstrating its stability and appeal, particularly for income-seeking investors.
- Diversified Portfolio: As of November 2025, Realty Income owns approximately 15,500 properties across all 50 U.S. states and seven European countries, with a high occupancy rate of 98.7%, providing robust support for its revenue.
- Strong R&D Investment: AbbVie offers a 3.1% dividend yield with an average annual increase of 7% over the past five years, and its nearly $11 billion investment in R&D underscores the company's confidence and commitment to future growth.
- Coca-Cola's Stability: Coca-Cola has a 2.9% dividend yield and has increased its dividend for 64 consecutive years; despite only a 1% growth in global sales in Q3, its brand strength and market demand ensure long-term stability.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 253.26 USD with a low forecast of 218.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
15 Buy
7 Hold
0 Sell
Moderate Buy
Current: 216.750
Low
218.00
Averages
253.26
High
289.00
Current: 216.750
Low
218.00
Averages
253.26
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
